Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia
NL-OMON46365Phase 2Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itraconazole in hereditary hemorrhagic telangiectasia (HHT), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Change in epistaxis severity score. Started Aug 2018; status: active, not recruiting.
02
Drugs
itraconazole
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON46365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46365.